3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Colorectal Neoplasms
1295
Pancreatic Neoplasms
819
Carcinoma, Hepatocellular
782
Stomach Neoplasms
754
Rectal Neoplasms
565
Esophageal Neoplasms
452
Colonic Neoplasms
414
Esophageal Squamous Cell Carcinoma
277
Neoplasm Metastasis
263
Cholangiocarcinoma
251
Liver Neoplasms
219
Neoplasms
200
Biliary Tract Neoplasms
179
Adenocarcinoma Of Esophagus
139
Gastrointestinal Stromal Tumors
108
Gallbladder Neoplasms
96
Adenocarcinoma
94
Breast Neoplasms
91
Gastrointestinal Neoplasms
89
Carcinoma, Non-Small-Cell Lung
87
Bile Duct Neoplasms
69
Sarcoma
67
Lung Neoplasms
64
Ovarian Neoplasms
60
Anus Neoplasms
59
Melanoma
54
Uterine Cervical Neoplasms
52
Carcinoma
48
Digestive System Neoplasms
45
Prostatic Neoplasms
40
Interventions
trifluridine tipiracil drug combination
1
Trastuzumab
1
Panitumumab
1
Oxaliplatin
1
Nivolumab
1
Bevacizumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Dihydropyrimidine Dehydrogenase Deficiency
×
Gastrointestinal
×
Clear all
NCT06245356
2025-12-10
TRIFLUOX-DP
UNICANCER
Phase 2
Recruiting
73 enrolled